1. Home
  2. GRBK vs AGIO Comparison

GRBK vs AGIO Comparison

Compare GRBK & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GRBK
  • AGIO
  • Stock Information
  • Founded
  • GRBK N/A
  • AGIO 2007
  • Country
  • GRBK United States
  • AGIO United States
  • Employees
  • GRBK N/A
  • AGIO N/A
  • Industry
  • GRBK Homebuilding
  • AGIO Biotechnology: Pharmaceutical Preparations
  • Sector
  • GRBK Consumer Discretionary
  • AGIO Health Care
  • Exchange
  • GRBK Nasdaq
  • AGIO Nasdaq
  • Market Cap
  • GRBK 2.9B
  • AGIO 2.5B
  • IPO Year
  • GRBK N/A
  • AGIO 2013
  • Fundamental
  • Price
  • GRBK $65.80
  • AGIO $24.25
  • Analyst Decision
  • GRBK Buy
  • AGIO Buy
  • Analyst Count
  • GRBK 2
  • AGIO 7
  • Target Price
  • GRBK $71.00
  • AGIO $37.33
  • AVG Volume (30 Days)
  • GRBK 213.0K
  • AGIO 1.8M
  • Earning Date
  • GRBK 10-29-2025
  • AGIO 10-30-2025
  • Dividend Yield
  • GRBK N/A
  • AGIO N/A
  • EPS Growth
  • GRBK N/A
  • AGIO N/A
  • EPS
  • GRBK 7.63
  • AGIO N/A
  • Revenue
  • GRBK $2,113,173,000.00
  • AGIO $44,791,000.00
  • Revenue This Year
  • GRBK N/A
  • AGIO $25.57
  • Revenue Next Year
  • GRBK $4.78
  • AGIO $153.24
  • P/E Ratio
  • GRBK $8.11
  • AGIO N/A
  • Revenue Growth
  • GRBK 6.62
  • AGIO 36.26
  • 52 Week Low
  • GRBK $50.57
  • AGIO $22.24
  • 52 Week High
  • GRBK $77.93
  • AGIO $62.45
  • Technical
  • Relative Strength Index (RSI)
  • GRBK 53.92
  • AGIO 25.99
  • Support Level
  • GRBK $61.40
  • AGIO $22.24
  • Resistance Level
  • GRBK $65.80
  • AGIO $25.98
  • Average True Range (ATR)
  • GRBK 1.63
  • AGIO 2.03
  • MACD
  • GRBK 0.24
  • AGIO -2.20
  • Stochastic Oscillator
  • GRBK 96.73
  • AGIO 9.05

About GRBK Green Brick Partners Inc.

Green Brick Partners Inc is a homebuilding and land development company. It acquires and develops land, as well as provides land and construction financing to its controlled builders. The company has three reportable segments: builder operations central, builder operations southeast, and land development. The majority of the company's revenue is generated from the builder operations central segment which is entirely the operations of builders in Texas. The company is engaged in various aspects of the homebuilding process, including land acquisition and development, entitlements, design, construction, marketing, sales, and brand image creation. In addition to homebuilding, the company provides home financing services, such as mortgage and title.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

Share on Social Networks: